Since 2015, large-scale cardiovascular outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of major adverse cardiovascular events, cardiovascular mortality, and heart failure hospitalization in patients with T2DM and established cardiovascular disease or high-risk profiles
Clinical evidence shows: 14 to 22% total body weight loss in clinical trials Preferential reduction of visceral (belly) fat over subcutaneous fat Improved insulin sensitivity within 4 to 8 weeks Reduced liver fat (NAFLD improvement) in 60 to 70% of patients Sustained appetite regulation
[Google Scholar] Hutchison's archives of surgery revisited
Baseline comprehensive metabolic panel including lipids, A1c, kidney and liver function, thyroid panel, and lipase
Impact of non-starter lactobacilli on release of peptides with angiotensin-converting enzyme inhibitory and antioxidant activities during bovine milk fermentation
But other enhancement ingredients have emerged as well, each targeting a different aspect of the weight loss journey